Dipeptidyl Peptidase-4 Inhibitors
In a 52-week active-comparator study, patients not achieving adequate glycaemic control on a metformin dose of at least 1500 mg/day were randomized to sitagliptin 100 mg once daily or glipizide,…
Epidemiology and Pathogenesis of Type 2 Diabetes
Related posts: The Incretin System Overview of Current Diabetes Management Bariatric Surgery for the Treatment of Type 2 Diabetes Sodium-glucose Cotransporter-2 Inhibitors Dipeptidyl Peptidase-4 Inhibitors The Incretin Mimetics
Sodium-glucose Cotransporter-2 Inhibitors
Figure 6.2 Adjusted mean (95% CI) percent change from baseline in body weight after 12 weeks of dapagliflozin treatment. Reproduced from List et al. (2009) with permission from the American…
Bariatric Surgery for the Treatment of Type 2 Diabetes
Related posts: The Incretin System Overview of Current Diabetes Management Sodium-glucose Cotransporter-2 Inhibitors Epidemiology and Pathogenesis of Type 2 Diabetes Dipeptidyl Peptidase-4 Inhibitors The Incretin Mimetics
Pipeline Diabetes Therapies
Related posts: The Incretin System Overview of Current Diabetes Management Sodium-glucose Cotransporter-2 Inhibitors Epidemiology and Pathogenesis of Type 2 Diabetes Dipeptidyl Peptidase-4 Inhibitors The Incretin Mimetics
Organization of Diabetes Care
CHAPTER 9 Organization of Diabetes Care Diabetes is a chronic illness that requires continuing medical care and patient education to prevent acute complications and to reduce the risk of long-term…
Overview of Current Diabetes Management
Related posts: The Incretin System Organization of Diabetes Care Sodium-glucose Cotransporter-2 Inhibitors Epidemiology and Pathogenesis of Type 2 Diabetes Dipeptidyl Peptidase-4 Inhibitors The Incretin Mimetics
The Incretin System
Related posts: Overview of Current Diabetes Management Organization of Diabetes Care Sodium-glucose Cotransporter-2 Inhibitors Epidemiology and Pathogenesis of Type 2 Diabetes Dipeptidyl Peptidase-4 Inhibitors The Incretin Mimetics
REDUCING CARDIOVASCULAR RISK
CHAPTER 4 REDUCING CARDIOVASCULAR RISK Understanding cardiovascular risk 86 Raised blood pressure 91 Dyslipidaemia 109 Obesity 121 Reducing platelet adhesiveness 125 Other risk factors 127 An “Alternative” view of targets…
THE ORGANISATION AND DELIVERY OF OPTIMAL DIABETES CARE
CHAPTER 7 THE ORGANISATION AND DELIVERY OF OPTIMAL DIABETES CARE Background to the changing organisation of diabetes services 186 Components of optimal organisation within primary care 189 Delivering high-quality care…
